FREE ACCESS

Sign in with Google to continue in the IIPLA Blog.

Google SSO gives you the quickest path into IIPLA analysis, reading access, and member-level continuity across articles. The full login page is still available if you prefer another option.

By continuing you agree to our terms and privacy policy.

Already have an account? Log in · Create account

Members-only content

IIPLA Blog
Monday, May 4, 2026
Patents

Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent

EP4615820 – “Crystalline Forms of Evenamide” is expected to extend asset exclusivity in EU into 2044 Evenamide is currently being investigated in Newron’s global ENIGMA-TRS Phase III development program, enrolling at least 1,000 schizophrenia patients with topline results expected in Q4-2026

IIPLA News Desk•anonymous access•0 articles left this week
Newron Further Expands Intellectual Property Portfolio for Evenamide with New EU Composition of Matter Patent
Sign In To Continue

You have reached the guest article limit.

Unlock more IIPLA analysis by signing in with SSO or joining as a member.

Sign in with SSOBecome a paid member
EP4615820 – “Crystalline Forms of Evenamide” is expected to extend asset exclusivity in EU into 2044 Evenamide is currently being investigated in Newron’s global ENIGMA-TRS Phase III development program, enrolling at least 1,000 schizophrenia patients with topline results expected in Q4-2026